What was Acepodia, Inc.’s price range in the past 12 months?
Acepodia, Inc. lowest stock price was TWD 10.85 and its highest was TWD 17.40 in the past 12 months.
What is Acepodia, Inc.’s market cap?
Acepodia, Inc.’s market cap is TWD 6.94B.
When is Acepodia, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Acepodia, Inc. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Acepodia, Inc. pay dividends?
Acepodia, Inc. does not currently pay dividends.
What is Acepodia, Inc.’s EPS estimate?
Acepodia, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acepodia, Inc. have?
Acepodia, Inc. has 583,197,100 shares outstanding.
Which hedge fund is a major shareholder of Acepodia, Inc.?
Currently, no hedge funds are holding shares in TW:6976
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acepodia, Inc.
Acepodia, Inc. is an advanced-stage biotechnology firm focused on pioneering cell-based treatments. The company utilizes its distinctive Antibody Cell Conjugation (ACC) platform technology to innovate therapeutic approaches and address critical unmet needs in oncology. Through this proprietary method, Acepodia engineers novel ACE therapies by precisely attaching tumor-specific antibodies to its specialized immune cells, such as gamma delta 2 T cells. Established in 2017, the company's corporate headquarters are situated in Grand Cayman, Cayman Islands.